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Abstract
Background: DNA vaccines represent promising therapeutic strategies in autoimmune disorders such as multiple
sclerosis (MS). However, the precise mechanisms by which DNA vaccines induce immune regulation remain largely
unknown. Here, we aimed to expand previous knowledge existing on the mechanisms of action of DNA vaccines in
the animal model of MS, experimental autoimmune encephalomyelitis (EAE), by treating EAE mice with a DNA
vaccine encoding the myelin oligodendrocyte glycoprotein (MOG), and exploring the therapeutic effects on the
disease-induced inflammatory and neurodegenerative changes.
Methods: EAE was induced in C57BL6/J mice by immunization with MOG35-55 peptide. Mice were intramuscularly
treated with a MOG-DNA vaccine or vehicle in prophylactic and therapeutic approaches. Histological studies were
performed in central nervous system (CNS) tissue. Cytokine production and regulatory T cell (Treg) quantification
were achieved by flow cytometry. Gene expression patterns were determined using microarrays, and the main
findings were validated by real-time PCR.
Results: MOG-DNA treatment reduced the clinical and histopathological signs of EAE when administered in both
prophylactic and therapeutic settings. Suppression of clinical EAE was associated with dampening of antigen (Ag)-
specific proinflammatory Th1 and Th17 immune responses and, interestingly, expansion of Treg in the periphery
and upregulation in the CNS of genes encoding neurotrophic factors and proteins involved in remyelination.
Conclusions: These results suggest for the first time that the beneficial effects of DNA vaccines in EAE are not
limited to anti-inflammatory mechanisms, and DNA vaccines may also exert positive effects through hitherto
unknown neuroprotective mechanisms.
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Background
The prevailing hypothesis to describe the pathogenesis
of multiple sclerosis (MS) is that myelin destruction
within the central nervous system (CNS) is due to anti-
gen (Ag)-specific autoimmunity [1,2]. Although the ma-
jority of currently used drugs for MS treatment target
immune responses, they are not selective for autoreac-
tive T cells. Furthermore, while effective in some cases,
current MS therapies may also alter host-protective im-
mune responses. Ideally, treatment strategies in MS
should aim to restore self-tolerance selectively to the
pathogenic autoantigens while leaving the healthy im-
mune system intact. One promising Ag-specific ap-
proach is DNA vaccination.
DNA vaccination involves the injection of naked DNA
that encodes target proteins under the control of a
eukaryotic promoter [3]. Although DNA immunization
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research has largely focused on eliciting protective im-
munity against a variety of infectious pathogens, the
technology may prove to have important applications in
autoimmune diseases such as MS [4,5]. Vaccination
using naked DNA encoding self-Ag has been shown to
protect and even reverse established disease in several
autoimmune animal models for various diseases, includ-
ing rheumatoid arthritis [6], insulin-dependent diabetes
mellitus [7] and MS [8]. Notably, recent clinical trials in
MS patients based on DNA vaccination with myelin
basic protein (MBP) demonstrated that the therapy was
safe and well tolerated, caused Ag-specific immune tol-
erance, and was associated with a reduction in MRI-
measured disease activity [9,10]. Despite the positive
results achieved by DNA vaccination in the treatment of
autoimmune disorders, the precise mechanisms of action
displayed by DNA vaccines remain undefined.
In the present study, we aimed to evaluate the precise
mechanisms by which a DNA vaccine encoding the mye-
lin oligodendrocyte glycoprotein (MOG) induces im-
mune regulation and efficiently suppresses experimental
autoimmune encephalomyelitis (EAE) in both prophy-
lactic and therapeutic settings. We observed that DNA
vaccination with MOG was proven to be effective in
ameliorating disease severity and reversing clinically
established EAE. Importantly, beneficial actions of DNA
vaccines encoding MOG were associated with downre-
gulation of Ag-specific Th1 and Th17 cellular immune
responses, increased frequency of natural CD4+CD25+




cDNAs of murine full-length MOG, MBP and proteolipid
protein (PLP) were obtained by retrotranscription and
PCR amplification of total RNA isolated from mouse brain







CCT-3’ for PLP. Fragments containing the myelin proteins
included EcoRI and NotI restriction sites that were used
for cloning. PCR products were inserted into the pCi plas-
mid, a cytomegalovirus promoter driven mammalian ex-
pression vector (Promega, Mannheim, Germany), digested
with EcoRI and NotI to create MOG-, MBP- and PLP-
DNA, respectively. The empty vector (pCi) was used as
control plasmid. Plasmid DNA was purified from the
transformed E. coli strain DH5α and sequenced to verify
integrity. Large-scale preparation of plasmid DNA was
conducted using Qiagen plasmid kits (Qiagen, Hilden,
Germany). Each preparation was checked by agarose gel
electrophoresis, and DNA concentration was measured by
optical density at 260 nm.
Mice
Five- to 8-week-old female C57BL6/J mice were pur-
chased from Harlan (Italy). Experiments were done
according to the EU regulations and approved by our in-
stitutional Ethics Committee on Animal Experimentation.
DNA vaccination
Mice were allocated to four groups and vaccinated with
plasmid DNA vaccines encoding MOG, PLP, or MBP, or
with the control plasmid (pCi). For prophylactic treat-
ment, 100 μg DNA/mouse in phosphate-buffered saline
(PBS) was injected intramuscularly in the tibialis anterior
muscle at 28 and 14 days before EAE induction. For
therapeutic treatment, mice received intramuscular (i.
m.) injections of DNA (100 μg/mouse) at days 10 and 24
postimmunization (p.i.).
EAE induction
Anesthetized mice were immunized by subcutaneous
injections of PBS containing 50 μg of MOG35-55 (Proteo-
mics Section, Universitat Pompeu Fabra, Barcelona,
Spain) emulsified in complete Freund's adjuvant (Sigma
Chemical, St Louis, MO, USA) supplemented with
2 mg/ml Mycobacterium tuberculosis H37RA (Difco La-
boratories, Detroit, MI, USA). The animals received an
additional intravenous injection of 150 ng Pertussis toxin
in 100 μl PBS on the day of immunization and again
48 h later. Mice were weighted and examined daily for
clinical signs of EAE, which were scored as follows:
grade 0, no clinical disease; grade 1, tail weakness or tail
paralysis; grade 2, hind leg paraparesis; grade 3, hind leg
paralysis; grade 4, paraplegia with forelimb weakness or
paralysis; grade 5, moribund state or death.
Histopathology and immunohistochemistry
Animals were killed with carbon dioxide (>70%) at day
32 p.i. Brain and spinal cord were removed, fixed over-
night in paraformaldehyde 4% and embedded in paraffin
wax. Brain and spinal cord were cut into 4-μm-thick ser-
ial sections. For histopathology, sections were stained
with hematoxylin and eosin (H&E), and Kluver-barrera
(KB). For immunohistochemistry, endogenous peroxid-
ase activity was blocked by incubating tissue sections in
hydrogen peroxide (2%), methanol (70%) and PBS for
20 min. Ag unmasking was developed in citrate 10 mM
(pH= 6), 10 mM Tris-EDTA (pH= 9), or protease type
XIV (Sigma Chemical). Non-specific protein binding was
blocked with 2% bovine albumin in PBS (blocking solu-
tion) at room temperature for 1 h. Sections were
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incubated overnight at 4 °C with the following primary
antibodies diluted in blocking solution: rabbit anti-CD3
(DakoCytomation, Glostrup, Denmark) (T lymphocytes)
dilution 1:100, Lycopersicon esculentum agglutinin
(LEA) (Sigma Chemical) (macrophages/microglia) dilu-
tion 1:100, rabbit anti- glial fibrillary acidic protein
(GFAP) (DakoCytomation) (astrocytes) dilution 1:500,
rabbit anti-Olig2 (Millipore, Billerica, MA, USA) (oligo-
dendrocytes) dilution 1:100, and mouse anti-200kD neu-
rofilament heavy (SMI-32) (Abcam, Cambridge, UK)
(axonal damage) dilution 1:100. All samples were incu-
bated at room temperature for 1 h with the following
secondary antibodies: biotinylated anti-rabbit or anti-
mouse IgG (DAKO) (1:200 dilution in blocking solu-
tion); the avidin–biotin-peroxidase complex (Immuno-
Pure ABC Peroxidase Staining Kits, Pierce, IL USA)
(1:100 dilution in PBS) was finally added for 1 h at room
temperature. The peroxidase reaction was visualized
with 2.5 mg/ml of 3,30-diaminobenzidine and 0.05%
hydrogen peroxide. As a background control, the pri-
mary antibody (Ab) incubation was omitted. No signal
was observed in any of the control slides.
Cell infiltration (H&E) was evaluated according to the
following criteria: 0 - no lesion; 1 - cellular infiltration
only in the meninges; 2, very discrete and superficial
infiltrates in parenchyma; 3, moderate infiltrate (less
than 25%) in the white matter; 4, severe infiltrates (less
than 50%) in the white matter; 5, more severe infiltrates
(more than 50%) in the white matter. Demyelination
(KB staining) was scored as follows: 0 - no demyelin-
ation; 1, little demyelination, only around infiltrates and
involving less than 25% of the white matter; 2, demyelin-
ation involving less than 50% of the white matter; 3, dif-
fuse and widespread demyelination involving more than
50% of the white matter.
Three randomly chosen areas (1 mm2) along the spinal
cord were analyzed in a blind manner. CD3-, GFAP- and
LEA-positive cells were counted in infiltrates manually.
SMI-32 and Olig2 quantification was performed with
the ImageJ analysis software.
Cytokine assays
Mice were killed 14 days p.i. with CO2 and spleens
removed. Splenocytes were prepared by grinding the
spleens through a wire mesh and cultured in 96-well
plates at 2 × 105 cells/well in a total volume of 200 μl of
Iscoves modified Dulbecco's medium (PAA Laboratories
GmbH, Pasching, Austria) supplemented with 10%
HyCloneW Fetal Clone I (Thermo Fisher Scientific, Wal-
tham, MA, USA), 50 μmol/ml of 2-mercaptoethanol
(Sigma Chemical), 2 mmol/ml of glutamine, 50 U/ml of
penicillin and 50 mg/ml of streptomycin, all obtained
from Gibco BRL (Paisley, UK). Cultures (three replicas)
were stimulated with 10 μg/ml of MOG35-55. Cells
cultured without any stimulus were used as baseline
controls. Cultures were incubated in a humidified at-
mosphere at 5% CO2 and 37 °C for 72 h. After stimula-
tion, supernatants were collected, and cytokine levels for
IFN-γ, IL-10, IL-4, and IL-17 were determined with the
FlowCytomix kit (Bender MedSystems, Burlingame, CA,
USA) according to the manufacturer’s recommendations.
GM-CSF (granulocyte-macrophage colony-stimulating
factor) levels were measured using a commercially avail-
able ELISA (R&D, Minneapolis, MN, USA).
Anti-MOG35-55 ab detection
Nunc-Immuno Plates (Nalgene Nunc International, Ros-
kilde, Denmark) were coated overnight with 0.1 μg/well
of MOG35–55. Serum samples were added in duplicate
and after extensive washes were incubated with a sec-
ondary horseradish peroxidase-conjugated goat anti-
mouse IgG (H+L). Upon addition of TMB Substrate Re-
agent Set (BD Pharmingen, San Jose, CA, USA), plates
were read at 450 nm in an ELISA reader.
Quantification of CD4+CD25+ FoxP3+ treg
Freshly isolated splenocytes (5 × 105) were washed with
PBS-azide and incubated with PerCP-labelled anti-CD45,
APC-Cy7-labeled anti-CD4, and PE-Cy7-labeled anti-
CD25 for 30 min at 4 °C. Cells were then washed, and
the intracellular detection of FoxP3 was conducted using
a commercial FoxP3 staining protocol (eBioscience, San
Diego, CA, USA). Data acquisition was performed on a
FACSCantoTM and analyzed with the DIVA software (BD
Pharmingen).
Gene expression microarrays
Total mRNA was extracted using TRI reagent (Sigma
Chemical) from CNS tissue. Expression was analyzed
with the Affymetrix Mouse Gene 1.0 Array using the
Ambion WT Expression kit (Applied Biosystems, Foster
City, CA, USA) for target amplification and WT Ter-
minal Labeling kit (Affymetrix, Santa Clara, CA, USA)
for target labeling. The gene-level log-scaled robust mul-
tiarray analysis (RMA) was performed with the Affyme-
trix Expression Console software. Linear models for
microarray data (LIMMA) R package [11] were used to
identify differentially expressed genes between the
MOG-DNA-treated and control plasmid-treated groups.
Genes that were observed as differentially expressed by
two-sample t-test with p-value <0.05 were considered
significant. Gene Ontology (GO) term enrichment was
performed by using Ontologizer 2.0 [12]. Data were ana-
lyzed with this program using a model-based gene set
analysis (MGSA) [13]. This method significantly reduces
the number of redundant categories returned by the
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classical gene-category analysis. Pathway enrichment
analysis was carried out with Ingenuity Pathway Analysis
(IPA). Microarray data are stored in the NCBI Gene Ex-
pression Omnibus repository and are available at http://
www.ncbi.nlm.nih.gov/geo/ with the entry number
GSE30482.
Real-time quantitative RT-PCR
Total mRNA was extracted from CNS tissue and retro-
transcribed as described above. RT-PCR was performed
using the ABI-Applied Biosystems 7900 HT Thermal
Cycler (Applied Biosystems) in 384 optical PCR plates.
Each reaction contained 2 μl standard/cDNA template,
10 μl of TaqMan Universal PCR Master Mix, No
AmpEraseW, UNG, 1 μl of corresponding TaqManW
Gene expression assay (Applied Biosystems), and 7 μl of
RNase free water following the standard PCR program
suggested by the manufacturer. mRNA expression levels
of glyceraldehyde-3-phosphate dehydrogenase (Gapdh),
brain-derived neurotrophic factor (Bdnf), neurotrophin-
5 (Ntf5), platelet-derived growth factor alpha (Pdgfa),
FoxP3, glial cell line-derived neurotrophic factor (GDNF)
family receptor alpha like (Gfral), GDNF family receptor
alpha 2 (Gfra2), GDNF family receptor alpha 4 (Gfra4),
and semaphorin-3 F (Sema3F) were determined by RT-
PCR relative quantification in MOG-DNA-treated and
control plasmid-treated mice. Briefly, the threshold cycle
(CT) value for each reaction, and the relative level
of gene expression for each sample were calculated
using the 2-ΔΔCT method [14]. To correct for loading
Figure 1 Prophylactic and therapeutic treatment of EAE with MOG-DNA vaccination ameliorates the clinical signs of the disease. EAE
was induced in female C57BL6/J mice with MOG35-55 peptide in CFA. Mice were vaccinated with i.m. injections of 100 μg of DNA according to
prophylactic (A) or therapeutic (D) protocols, as described in Methods. Two groups of mice (n = 5) were subjected to DNA treatment with the
full-length MOG-DNA construct (□) or plasmid control (■) in prophylactic (B) or therapeutic (E) settings. Disease parameters in mice treated
prophylactically and therapeutically are shown in tables (C and F). Mean clinical scores are plotted against the number of days after EAE
induction. Disease scores are expressed as mean values (SEM). aIndicates cumulative disease scores at 30 days p.i.; statistically significant
differences obtained by Student’s t-tests are denoted with asterisks (*p< 0.05; **p< 0.005). Results shown are representative of two independent
experiments.
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differences, the values were normalized according to the
level of expression of the housekeeping gene, Gapdh,
within each sample. Its CT value was subtracted from
that of the specific genes to obtain a ΔCT value. Differ-
ences (ΔΔCT) between the ΔCT values obtained for the
control plasmid (calibrators) and the ΔCT values for the
MOG-DNA groups were determined. The relative quan-
titative value was then expressed as 2-ΔΔCT, representing
the fold change in gene expression normalized to the en-
dogenous control and relative to the calibrators. Samples
were determined in triplicates. Analysis was performed
with the software SDS 2.3 (Applied Biosystems).
Statistical analysis
Statistical analysis was performed by using the SPSS 17.0
package (SPSS Inc, Chicago, USA) for MS-Windows.
Depending on the applicability conditions, Mann–Whit-
ney test or Student’s t-test were used for comparisons of
mean values between groups. Differences were consid-
ered statistically significant when p-values were below
0.05. Descriptive data are presented as mean values
(standard error of the mean - SEM) unless otherwise
stated.
Results
Vaccination with DNA encoding MOG protects against
EAE induction
To evaluate whether the injection of DNA encoding
MOG cDNA can be effective in protecting mice from
EAE induction, female C57BL6/J mice were first vacci-
nated with MOG-DNA or control plasmid (pCi) as
described in Methods and depicted in Figure 1A. Mean
clinical disease scores were significantly lower in mice
vaccinated with the MOG-DNA plasmid vector com-
pared with the control plasmid group (Figure 1B).
Prophylactic MOG-DNA treatment also delayed disease
onset [mean (SEM): 10.6 days (0.7) in MOG-DNA-
treated mice vs. 7.5 days (0.3) in control plasmid-treated
mice; p= 0.006], and reduced clinical severity [mean cu-
mulative clinical scores: 1.4 (0.4) vs. 3.8 (0.3) in MOG-
DNA-treated and control plasmid-treated mice respect-
ively; p= 0.003] (Figure 1C).
In order to investigate whether these findings were
specific for MOG-DNA vaccination or were also
observed with other myelin autoantigens, mice were
vaccinated with plasmid DNA vaccines encoding MBP
or PLP (antigenic controls) using the same above-
mentioned prophylactic protocol. As shown in Add-
itional file 1, vaccination with DNA encoding MBP
was also associated with a significant reduction in dis-
ease severity, although to a lesser degree compared
with MOG-encoding DNA vaccines [mean cumulative
clinical scores: 2.5 (0.1) vs. 3.8 (0.3) in MBP-treated
and control plasmid-treated mice respectively;
p= 0.003]. Finally, EAE disease course was similar be-
tween PLP-DNA-treated and control plasmid-treated
mice (Additional file 1).
MOG-DNA vaccination ameliorates ongoing EAE
We next addressed the question of whether MOG-DNA
vaccination could reverse clinically established EAE. To
this end, mice were left untreated until disease onset
and subsequently vaccinated with MOG-DNA or vector
DNA alone, as depicted in Figure 1D. Interestingly,
therapeutic MOG-DNA treatment improved ongoing
EAE, as reflected by the significant reduction in the
mean cumulative EAE clinical score observed in MOG-
DNA-treated mice compared with control plasmid-
treated mice [2.2 (0.1) vs. 3.0 (0.3); p= 0.031] (Figure 1E
and F).
These findings were specific for MOG-DNA treated
mice, as mean EAE disease scores did not significantly
differ between mice receiving therapeutic treatment with
antigenic controls (MBP or PLP) and control plasmid
(Additional file 1).
CNS pathology is reduced by vaccination with MOG-
encoding DNA
To assess whether EAE clinical improvement was ac-
companied by decreased neuropathology, histopatho-
logical studies were performed in CNS tissue from pCi
and MOG-DNA treated mice. H&E and KB staining
showed that mice treated with pCi had perivascular cuffs
and extensive inflammatory infiltration in the white mat-
ter of the spinal cord (Figure 2A), as well as demyelin-
ation in areas with moderate to severe inflammatory
infiltration (Figure 2B). Mice treated with MOG-DNA,
on the other hand, were overall characterized by less se-
vere CNS inflammation (Figure 2A) and significant
reductions in microglia/macrophage activation (Fig-
ure 2D), astrogliosis (Figure 2E) and axonal damage (Fig-
ure 2F). Although demyelination and T cell infiltration
were also reduced in MOG-DNA treated mice, differ-
ences did not reach statistical significance (Figures 2B
and C respectively).
MOG-DNA-treated animals show reduced MOG35-55-
specific T cell responses
Based on the findings of a reduction in both EAE disease
course and CNS pathology in MOG-DNA treated mice,
we performed additional experiments in order to
characterize the mechanisms by which MOG-encoding
DNA vaccines produce their beneficial effects in EAE.
All these experiments were conducted in mice vacci-
nated according to the prophylactic protocol described
in Methods. We first measured MOG35-55-induced T cell
immune responses by determining ex vivo the levels of
Th1, Th2, and Th17 cytokines using flow cytometry. As
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shown in Figure 3A, levels of the proinflammatory cyto-
kines IFN-γ and IL17 were significantly reduced in mice
vaccinated with MOG-encoding DNA compared to mice
treated with control plasmid (p= 0.016 for IFN-γ;
p= 0.013 for IL-17). However, levels of the anti-
inflammatory cytokine IL-4 did not significantly differ
between MOG-DNA treated and pCi-treated mice
(p= 0.320; Figure 3A). Finally, levels of IL-10 in superna-
tants from stimulated mice splenocytes were below the
detection limit of the technique.
Based on the IFN-γ and IL17 findings we also mea-
sured the levels of GM-CSF, which is known to play
important roles in Th17 and Th1 cell function [15,16].
Supporting the IFN-γ and IL17 data, MOG-DNA treat-
ment was associated with a trend towards decreased
GM-CSF levels compared with plasmid-control mice
[mean (SEM): 179.5 pg/ml (121.3) vs. 337.6 pg/ml
(44.2) respectively; p= 0.065, Mann-Whitney U test)].
Altogether, these observations suggest that MOG-
DNA vaccines exert some of their protective effects in
Figure 2 MOG-DNA therapy decreased neuropathology associated with EAE. Representative histopathologies of the spinal cord 32 days
post-EAE induction in mice previously treated either with MOG-DNA or plasmid control according to a prophylactic protocol. Spinal cords were
stained to evaluate cell infiltration (H&E; A), demyelination (KB; B), T cell infiltration (CD3; C), microglia/macrophage activation (LEA; D), reactive
astrogliosis (GFAP; E), and axonal damage (SMI-32; F). Bar graphs represent mean number of cells/mm2 (SEM) observed in one representative
experiment with five mice per group.
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EAE by inhibiting the secretion of proinflammatory
cytokines such as IFN-γ and IL-17 rather than inducing
Th2-type immune responses.
Anti-MOG B cell responses are not altered by DNA
vaccination
In order to characterize the autoreactive B-cell responses
in vaccinated EAE mice, the presence of MOG-specific
antibodies was determined in serum samples by ELISA.
Anti-MOG antibodies were detected in all animals; how-
ever, Ab titers in MOG-DNA vaccinated mice were simi-
lar to those observed in control plasmid-treated mice
(Figure 3B).
MOG-DNA vaccination induces an expansion of Treg
We next investigated whether treatment with MOG-
DNA vaccines promoted the development of Treg in
EAE animals. As shown in Figure 4A, the percentage of
CD4+CD25+FoxP3+ Treg determined by flow cytometry
was significantly higher in splenocytes from MOG-
DNA-treated mice compared with animals treated with
the empty plasmid [20.5% (3.9) vs. 9.3% (1.7), p= 0.025].
Given the potential of Treg to migrate into the CNS in
response to inflammation, we also determined the ex-
pression of the Treg-specific transcription factor FoxP3
in CNS tissue from EAE mice by RT-PCR. Interestingly,
MOG-DNA vaccination was associated with a significant
increase in CNS FoxP3 mRNA expression levels com-
pared with the control plasmid-treated condition
(p= 0.014; Figure 4B). Taken together, these findings
suggest that DNA vaccination with MOG may produce
its beneficial effects through an expansion of the Treg
population in the periphery and subsequent accumula-
tion of Treg in the CNS.
cDNA microarrays reveal downregulation of inflammatory
genes and upregulation of neuroprotective genes in
MOG-DNA-vaccinated mice
In order to characterize the mechanisms of action asso-
ciated with the efficacy of MOG-DNA vaccines, we
determined the gene expression profiles induced by
DNA vaccination in the CNS using cDNA microarrays.
A total of 2,462 genes were differentially expressed be-
tween MOG-DNA-treated and control plasmid-treated
mice (p< 0.05). Of these, 1,382 genes were downregu-
lated and 1,080 up-regulated in the MOG-DNA-treated
group. In agreement with the pathological findings, gene
enrichment analysis using the GO terms revealed the in-
flammatory response category to be the most repre-
sented among downregulated genes in mice vaccinated
Figure 3 Effect of MOG-DNA vaccination in T and B cell immune responses. (A) Splenocytes isolated at day 14 p.i. from mice challenged for
EAE induction with MOG35-55 and previously vaccinated with DNA (MOG or pCi) were incubated in the presence (stimulated) or absence (control)
of MOG35–55 (10 μg/ml) for 48 h. Cytokine production in cell culture supernatants was determined by flow cytometry. Bars indicate mean values
(SEM) in pg/ml of five mice per group. *p= 0.016 for IFN-γ and p= 0.013 for IL-17 (Student’s t-test). Results shown are representative of two
independent experiments. (B) Serum samples from EAE mice treated with MOG-DNA or pCi were obtained at day 30 p.i., and anti-MOG35-55 IgG
titers were determined by ELISA. Error bars indicate mean values and SEM. Data represent a pool of three different experiments.
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with MOG-DNA (Table 1). A detailed list of differen-
tially expressed genes involved in the inflammatory
process is provided in Additional file 2. In order to iden-
tify the cellular pathways induced by the effect of MOG-
DNA vaccination, a more in depth functional enrichment
analysis was performed with the Ingenuity software. Of
note, one of the top enriched pathways that contained a
high percentage of upregulated genes in the MOG-DNA-
treated group was the axonal guidance signaling pathway
(Additional file 3), which included genes coding for
neurotrophic factors and proteins involved in the remye-
lination process. These findings pointed to a potential
mechanism of action of MOG-DNA vaccines upregulat-
ing genes with neuroprotective roles. A search for add-
itional neuroprotective genes (summarized in Table 2)
was performed in order to validate microarray findings
by an alternative technique.
As depicted in Figure 5, gene expression levels for
neurotrophic factors determined by RT-PCR were over-
all found to be increased in mice vaccinated with MOG-
encoding DNA compared with mice receiving control
plasmid, and microarray differences were validated for
Bdnf (p= 0.029); Gfra2 (p= 0.039) and Gfra4 (p= 0.003).
A trend towards higher expression levels was also
observed for Ntf5 (p= 0.093), whereas differences for
Gfral did not reach statistical significance (p= 0.258).
Promotion of remyelination by MOG-DNA vaccination
In microarray studies, two of the neuroprotective genes
that were up-regulated in the MOG-DNA treated group,
Pdgfa and Sema3f, are known to be involved in the
remyelination process (Table 2) and hence were also
selected for validation. As shown in Figure 6A, Pdgfa
was found to be significantly overexpressed by RT-PCR
in MOG-DNA vaccinated mice (p= 0.017), whereas the
increased expression levels observed for Sema3f did not
reach statistical significance (p= 0.178).
In order to provide histopathological evidence for a po-
tential positive effect of DNA vaccines in remyelination, we
also determined the expression of the transcription factor
Olig2, a marker strongly expressed in oligodendrocyte pro-
Figure 4 Frequency of splenic Foxp3+-Treg in the periphery and mRNA expression of Foxp3 in the CNS after MOG-DNA vaccination. (A)
Percentage of CD4+CD25+Foxp3+ Treg in the total CD4+ T cell population observed in spleens isolated from MOG- or pCi-treated mice (n = 6/
group) at day 14 p.i. Frequency of Treg was determined by flow cytometry and bars represent mean percentage of positive cells (SEM). *p= 0.025
(Student’s t-test). (B) Foxp3 mRNA expression levels in CNS tissue from DNA vaccinated animals at day 14 after EAE induction. FoxP3 expression
was determined by RT-PCR using Gapdh as endogenous control. Results are expressed as fold change in gene expression in MOG-DNA treated
mice relative to plasmid control mice (calibrators). *p= 0.014 (Student’s t-test).
Table 1 Top-scoring gene ontology categories down-regulated in mice vaccinated with MOG-encoding DNA
GO ID Category MGSAa Enrichmentb Expressionc
GO:0006954 Inflammatory response 0.935 4.1 Downregulated
GO:0002376 Immune system process 0.758 3.2 Downregulated
GO:0030133 Transport vesicle 0.719 3.9 Downregulated
GO:0000323 Lytic vacuole 0.609 4.3 Downregulated
GO:0015914 Phospholipid transport 0.511 4.1 Downregulated
GO-oriented analysis with differentially expressed genes obtained with microarrays from brain and spinal cord tissue was conducted in order to classify
biologically related genes. Ontologizer 2.0 software was used for GO term enrichment analysis.
aMGSA: score obtained using a model-based gene set analysis. Only categories with a score >0.5 are represented.
bEnrichment values indicate how many times genes from the corresponding GO categories are overrepresented in the list of differentially expressed genes
compared to the list of random genes.
cExpression: refers to the direction in gene expression observed in MOG-DNA treated mice (n = 5) versus plasmid control mice (n = 5). GO ID: GO identification.
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genitor cells (OPC) [17], in CNS tissue of vaccinated mice.
Interestingly, a trend towards higher numbers of Olig2+
progenitor cells was observed in MOG-DNA-treated mice
compared with plasmid control mice (p=0.07; Figure 6B),
suggesting that OPC are augmented in demyelinated CNS
lesions from mice vaccinated with MOG-DNA.
Figure 5 Induction of neurotrophic factors in EAE mice treated with MOG-DNA. mRNA expression levels for each gene were determined in
CNS tissue by RT-PCR relative quantification, as described in Methods. Gapdh was used as endogenous control. Graphs indicate fold changes in
gene expression in MOG-DNA treated mice relative to plasmid control mice (calibrators). ΔCT values were compared by means of Student’s t
tests. Statistically significant differences are shown with asterisks.
Table 2 Summary of selected genes with neuroprotective functions found up-regulated with microarrays in MOG-DNA-
treated mice
Affymetrix probe set Genes Description Gene IDa FCb I-value
Neurotrophic factors
10595050 Gfral GDNF family receptor alpha like 404194 1.37 0.0186
10416340 Gfra2 GDNF family receptor alpha 2 14586 1.34 0.0030
10487787 Gfra4 GDNF family receptor alpha 4 14588 1.40 0.0475
10552938 Ntf5 Neurotrophin 5 78405 1.29 0.0212
10474399 Bdnf Brain-derived neurotrophic factor 12064 1.38 0.0487
Remyelination
10596747 Sema3f Semaphorin 3 F 20350 1.32 0.0133
10526880 Pdgfa Platelet-derived growth factor, alpha 18590 1.41 0.0389
Differentially expressed genes obtained with microarrays between MOG-DNA-treated mice (n = 5) and control plasmid-treated mice (n = 5) were estimated using
Student’s t test, as described in Methods.
aRefers to Entrez gene ID.
bFold change expression in MOG-DNA-treated mice versus control plasmid-treated mice. Data represent the mean ratio of five arrays. GDNF: glial cell line derived
neurotrophic factor.
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Altogether these findings point to a potential neuro-
protective effect of MOG-DNA vaccines favouring the
remyelination process.
Discussion
In this study, we investigated on the mechanisms
involved in the therapeutic effects of vaccination with
plasmid DNA encoding the encephalitogenic MOG pro-
tein on the inflammatory and neurodegenerative pro-
cesses taking place during EAE disease course. We
observed that vaccination with MOG-DNA improved
both, prophylactically and therapeutically, clinical and
histopathological signs of EAE. Mechanistic studies
showed that protection from disease by MOG-DNA was
accompanied by (i) decreased levels of the pro-
inflammatory cytokines IFN-γ and IL-17; (ii) expansion
of Treg in the periphery and increased mRNA expres-
sion levels in the CNS of the Treg-specific transcription
factor FoxP3; (iii) down-regulation of genes involved in
the inflammatory process and up-regulation of genes
with neuroprotective functions.
A DNA vaccine encoding the full-length MBP molecule
(BHT-3009) has been used in clinical trials to evaluate
safety in MS patients [9,10]. DNA vaccines were found to
be safe and demonstrated efficacy reducing brain MRI le-
sion activity. Although previous studies have mostly been
performed on MBP, in our study we focused on MOG as
the primary target autoantigen. Even though it is only a
minor protein constituent of myelin (less than 0.05%),
MOG is exclusively expressed in the CNS and is located
on the surface of the myelin sheaths that surround neur-
onal axons [18]. Besides, in several animal models
immunization with MOG causes inflammatory demyelin-
ating lesions that are virtually indistinguishable from the
active demyelinating plaques characteristic of MS [19].
Prophylactic treatment of EAE mice with MOG-DNA
vaccines decreased disease severity, delayed disease
onset, and reduced inflammation- and axonal damage-
related CNS pathology. Unexpectedly, one of the anti-
genic controls, MBP, had also a positive effect on EAE
disease course, albeit it did not modify the onset of dis-
ease. Of note, therapeutic treatment with plasmids en-
coding MOG, but not with MBP or PLP, resulted in
amelioration of ongoing EAE. These data may set the ra-
tionale for the use of MOG-based DNA vaccines to treat
MS patients, rationale that is further reinforced by the
positive results observed in the mechanistic experiments
conducted in the study and discussed below.
Figure 6 Promotion of remyelination in mice vaccinated with MOG-DNA. (A) Changes in mRNA expression levels for Pdgfa and Sema3f were
determined in CNS from DNA-vaccinated mice on day 14 after EAE induction using RT-PCR relative quantification. A statistically significant
increase was observed for Pdgfa (p= 0.017) in the group of animals vaccinated with MOG vs. pCi; for Sema3f, differences in expression did not
reach statistical significance (p= 0.178). All values are normalized to Gapdh mRNA. (B) Expression of Olig2 by OPC was examined in spinal cords of
MOG-DNA and plasmid control mice (brown staining). Quantification revealed that Olig2+-cells were increased in the CNS after treatment with
DNA encoding MOG compared to control animals.
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The profile of T cell reactivity to MOG35-55 after
MOG-DNA vaccination showed a dramatic impairment
of the IFN-γ and IL-17 responses at the peak of the dis-
ease. This may explain why DNA vaccination suppresses
EAE, since these cytokines are known to be crucial in
EAE [20,21]. The suppressive effect of DNA vaccination
was both Th1 and Th17 cell-specific, as only IFN-γ and
IL-17 responses were affected in the spleen, and the ex-
pression of relevant Th2 cytokines such as IL-4 and IL-
10 were not altered by DNA vaccination. Although a
beneficial Th2 bias has been reported in EAE [22,23], in
our study we could not detect any measurable alteration
of the Th1/Th2 balance of encephalitogenic T cells. In
this regard, such Th2-driven effect was only observed
when the myelin Ag present in the DNA vaccine were
delivered along with DNA encoding IL-4 [22].
Comparable anti-MOG Ab titers were obtained in the
blood of DNA-treated and control animals. This finding
is most likely explained by the higher induction of anti-
MOG antibodies in animals exhibiting clear clinical
signs of EAE (control group) and the increase in the
levels of anti-MOG antibodies induced by MOG-
encoding DNA vaccines (MOG-DNA group) [24].
An interesting finding in our study was the expansion
of Treg in the periphery observed in mice treated with
MOG-DNA vaccines, together with an increase of
mRNA FoxP3 expression in the CNS. Unfortunately, the
Treg suppressive function and proportion of CNS infil-
trating Treg cells was not investigated in our study and
should be considered in future studies of DNA treat-
ment in EAE. Absence of CD4+CD25+FoxP3+ natural
suppressor T cells has been shown to enhance the devel-
opment of T cell-mediated autoimmunity, whereas adop-
tive transfer of these cells was associated with opposite
effects [25,26]. Considering that Th17 and induced Treg
are activated through reciprocal mechanisms [27,28], the
reduced IL-17 production by Th17 cells reported herein
could be caused by enhanced activation of induced Treg
during DNA vaccination. Contrary to our data, treat-
ment of rat MOG91-108-EAE with a plasmid DNA vac-
cine encoding the MOG91-108 peptide was found to
reduce the expression of FoxP3 in the periphery [29] or
to have no effect on CD25 expression [30]. Our results
are, however, in line with previous reports showing that
DNA vaccination is able to induce Treg and protect ani-
mals against other organ specific autoimmune diseases
such as autoimmune diabetes [31] and uveitis [32]. Con-
sidering the reports on impaired number and function
of Treg in MS [33-35], therapies associated with an ex-
pansion of this suppressor T cell population may be de-
sirable to treat patients with MS.
Another interesting finding in the present study was the
up-regulation of genes encoding neurotrophic factors and
proteins involved in remyelination in the CNS of MOG-
DNA treated mice. In this context, while a variety of anti-
inflammatory mechanisms have been described for DNA
treatment in EAE (i.e., down-regulation of myelin protein-
specific Th1 immune responses [36], increased Th2
responses [22], induction of IL-10 producing type 1 regu-
latory T cells [37] and up-regulation of IFNβ [30]), poten-
tial neuroprotective effects of DNA vaccines were not
previously reported and represent a novel finding.
A number of studies support a role of neurotrophic
factors such as the neurotrophins BDNF and Ntf5, and
the growth factor GDNF together with its receptors
(GFRAL, GFRA1-4) in neuroprotective and anti-
inflammatory activities in both EAE and MS [38-42].
Particularly, numerous studies report positive effects of
BDNF directly in the CNS stimulating tissue repair after
traumatic injury [43]. The neuroprotective activities per-
formed by neurotrophic factors also include improve-
ment of myelin repair by stimulating the proliferation of
OPC or by enhancing oligodendrocyte regeneration [38].
In the current study, MOG-DNA vaccines enhanced the
expression in CNS tissue of genes involved in neuropro-
tection such as Bdnf, Ntf5, and Gdnf receptors. These
findings may represent one of the mechanisms of action
whereby MOG-DNA vaccination exerts its protective
effects in EAE restoring the injured CNS tissue via an
increased production of neurotrophic factors.
Related with the potential induction of neuroprotective
effects shown by MOG-DNA vaccines, an up-regulation
of genes involved in remyelination such as Pdgfa [44] was
also observed in treated mice. During development, OPC
numbers are limited by the supply of Pdgfa and, for in-
stance, previous studies have suggested the possibility of
increasing the OPC population density in demyelinating
areas by artificially enhancing Pdgfa supply [45]. More-
over, experiments in transgenic mice for the human
PDGFA revealed increased oligodendrocyte generation
and survival that promoted remyelination of chronic
lesions [46]. In this setting, therapies that boost PDGFA
production in the CNS tissue may have an attractive
added value in MS. Although we do not have a direct evi-
dence of remyelination, in our study the increased expres-
sion of Olig2+ cells induced by MOG-DNA treatment
indicates augmented numbers of OPC in the spinal cords
of the animals. Ultimately, these cells may have the poten-
tial to migrate, proliferate and, subsequently, differentiate
into myelin-forming cells.
Altogether, these results suggest that the protective
effects of MOG-DNA vaccines in EAE are not limited to
anti-inflammatory mechanisms, and DNA vaccines may
also act inducing neuroprotection. These findings have
important clinical implications. In a complex disorder like
MS in which two distinct components, inflammatory and
neurodegenerative, clearly contribute to disease pheno-
type, therapeutic strategies targeting both components
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should prove to be more beneficial for the disease than
those targeting each component in isolation. It is import-
ant to highlight that the neurodegenerative component of
the disease underlies the treatment-resistant progressive
forms of MS which are associated with important neuro-
logical disability. In this setting, therapies with neuropro-
tective effects are needed for the disease.
Conclusions
In the present study DNA vaccination with MOG has
demonstrated efficacy in improving EAE disease severity
when administered both prophylactically and therapeut-
ically to mice. Furthermore, the beneficial effects of
MOG-DNA vaccines were accompanied by a reduction
of pro-inflammatory cytokines, expansion of Treg, and
up-regulation of neuroprotective genes. Although these
positive findings are based on the animal model of MS,
altogether our data may provide the rationale for using
MOG-DNA vaccines to treat MS patients in phase I/II
clinical trials.
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